Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

Tudor‐Eliade Ciuleanu; Thomas Brodowicz; Christoph Zielinski; Joo Hang Kim; Maciej Krzakowski; Eckart Laack; Yi‐Long Wu; Isabel Bover; Stephen Begbie; Valentina Tzekova; Branka Čučević; José Rodrigues Pereira; Sung Hyun Yang; Jayaprakash Madhavan; Katherine P. Sugarman; Patrick Peterson; William J. John; Kurt Krejcy; Chandra P. Belani

doi:10.1016/s0140-6736(09)61497-5

Keywords

PemetrexedMedicineTolerabilityInternal medicinePlaceboClinical endpointHazard ratioLung cancerMaintenance therapyChemotherapySurgeryAdverse effectRandomized controlled trialGastroenterologyConfidence intervalCisplatin

Affiliated Institutions

Related Publications

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Filippo de Marinis , Mircea Dediu +14 more

Purpose In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62; 95% CI, 0....

2013 Journal of Clinical Oncology 626 citations

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

Shirish M. Gadgeel , Delvys Rodríguez‐Abreu , Giovanna Speranza +23 more

PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo ...

2020 Journal of Clinical Oncology 1095 citations

Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data

Dorothea Wagner , Wilfried Grothe , Johannes Haerting +3 more

Purpose This systematic review and meta-analysis were performed to assess the efficacy and tolerability of chemotherapy in patients with advanced gastric cancer. Methods Randomi...

2006 Journal of Clinical Oncology 1179 citations

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Axel Grothey , Eric Van Cutsem , Alberto Sobrero +17 more

No treatment options are available for patients with metastatic colorectal cancer that progresses after all approved standard therapies, but many patients maintain a good perfor...

2012 The Lancet 2789 citations

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Richard S. Finn , Baek‐Yeol Ryoo , Philippe Merle +17 more

PURPOSE Pembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial in previously treated patients with advanced hepatocellular carcinoma (HCC). K...

2019 Journal of Clinical Oncology 1737 citations

Publication Info

Year: 2009
Type: article
Volume: 374
Issue: 9699
Pages: 1432-1440
Citations: 1111
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1111

OpenAlex

Cite This

APA Style

                            
                                
                                    Tudor‐Eliade Ciuleanu, 
                                
                                    Thomas Brodowicz, 
                                
                                    Christoph Zielinski
                                
                                et al.
                            
                            (2009). 
                            Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. 
                            The Lancet
                            , 374
                            (9699)
                            , 1432-1440.
                            https://doi.org/10.1016/s0140-6736(09)61497-5
                        

Identifiers

DOI: 10.1016/s0140-6736(09)61497-5